Low-Dose Iloprost Infusion Improves Insulin Action in Aged Healthy Subjects and NIDDM Patients
- Giuseppe Paolisso, MD,
- Giosue Di Maro, MD,
- Anna D'Amore, MD,
- Nicola Passariello, MD,
- Antonio Gambardella, MD,
- Michele Varricchio, MD and
- Felice D'Onofrio, MD
- Address correspondence and reprint requests to Giuseppe Paolisso, MD, Dipartimento di Geriatria e Malattie Metaboliche, Servizio di Astanteria Medica, I Policinico, Piazza Miraglia 2, 1–80138 Naples, Italy.
Abstract
OBJECTIVE To investigate the effect of iloprost infusion on insulin action.
RESEARCH DESIGN AND METHODS Thirteen healthy subjects and 13 non-insulin-dependent diabetes mellitus (NIDDM) patients matched for age (68.2 ± 0.5 vs. 67.9 ± 0.5 years, NS), gender ratio (7 men:6 women vs. 6 men:7 women), body weight, body fat distribution, arterial blood pressure, and plasma triglycéride levels (1.89 ± 0.09 vs. 1.87 ± 0.08 mmol/l, NS) were studied. In eight healthy subjects and eight NIDDM patients, we studied insulin action by euglycemic glucose clamp (insulin infusion rate 2 mU · kg−1 · min−1) along with saline and iloprost delivery (0.7 ng · kg−1 · min−1). In the other five subjects of each group, forearm blood flow and insulin-mediated glucose uptake during saline and iloprost infusion (0.7 ng · kg−1 · min1) were investigated.
RESULTS Iloprost infusion improved insulin-stimulated whole-body glucose uptake and oxidative and nonoxidative glucose metabolism in both study groups. Forearm blood flow under basal conditions and with insulin infusion (2 mU · kg−1 · min−1) did not show any significant difference from that during saline and iloprost infusion (0.7 ng · kg−1 · min−1) in healthy subjects and diabetic patients.
CONCLUSIONS Iloprost infusion improves insulin action in healthy subjects and NIDDM patients.
- Received June 13, 1994.
- Revision received October 22, 1994.
- Accepted October 22, 1994.
- Copyright © 1995 by the American Diabetes Association
